By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


IMPAX Laboratories 

30831 Huntwood Avenue

Hayward  California  94544  U.S.A.
Phone: 510-476-2000 Fax: 510-471-3200

Our Mission

Our mission is to be to become a leader in the development, manufacturing and marketing of specialty prescription pharmaceutical products utilizing our formulation expertise and unique drug delivery technologies. Impax Laboratories commits itself to the highest standards of integrity in contributing to the best interests of patients, the medical profession, our employees and our communities, and to seeking significant returns to our stockholders based on the continued pursuit of excellent science.

Company Profile

The December 1999 merger of IMPAX Pharmaceuticals, Inc. and Global Pharmaceutical Corporation formed a new organization named IMPAX Laboratories, Inc. IMPAX Laboratories, Inc. (Nasdaq:IPXL), a Delaware corporation, is headquartered in Hayward, California. This 36,000 square foot facility also serves as the primary development center for the new organization. A second facility, located in Philadelphia, Pennsylvania, serves as our primary commercial center, with sales, marketing and distribution occurring in this 113,000 square foot facility. All commercial manufacturing will be performed at IMPAX's California location, while the IMPAX facility in Philadelphia will perform packaging, repackaging and distribution functions for all finished products. Overall, we currently employ more than 180 people.

Our Strategic Focus

IMPAX Laboratories is focusing on three key areas :

Drug Delivery Technology: We have been engaged in developing technologies for the formulation of controlled-release oral pharmaceuticals utilizing both proprietary and non-proprietary drug delivery technologies.,

Niche Multi Source Pharmaceutical Products (Our Hayward facility has a strong development and technology base that allows us to target difficult products such as those utilizing modified or controlled-release. We are applying our patented and non-patented drug delivery technologies discussed above to the development of generic versions of selected, controlled-release brand name pharmaceuticals), and

Branded Pharmaceutical Products
(currently developing and evaluating its branded product strategy and focus. Our initial focus will be in building a portfolio of products used for treating disorders of the central nervous system (CNS). Our strategy to build this portfolio includes a combination of licensing, acquisition, and internal development. We intend to utilize our drug delivery technologies in the formulation of off-patent drugs as modified or controlled release pharmaceutical products that we will market as branded products.).

Last Updated: 12-15-16

Key Statistics

Ownership: Public

Web Site: IMPAX Labs
Employees: 180
Symbol: IPXL


Drug Delivery

Company News
Bay Area's IMPAX Labs (IPXL) Surges on Merger Buzz 9/22/2017 5:53:55 AM
IMPAX Labs (IPXL) Announces Settlement Of Contract Litigation On Opana ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets 8/7/2017 7:51:12 AM
IMPAX Labs (IPXL) Announces FDA Approval Of Its AB Rated Generic Concerta (Methylphenidate Hydrochloride) Extended-Release Tablets CII 7/17/2017 6:26:41 AM
IMPAX Labs (IPXL) Announces FDA Approval And Launch Of Additional Strengths Of Generic Focalin XR (Dexmethylphenidate Hydrochloride) Extended-Release Capsules CII 7/6/2017 6:36:31 AM
IMPAX Labs (IPXL) To Report Second Quarter 2017 Results On August 9, 2017 6/29/2017 9:25:39 AM
IMPAX Labs (IPXL) Reports First Quarter 2017 Financial Results 5/10/2017 11:25:11 AM
IMPAX Labs (IPXL) Announces FDA Approval And Launch Of A Generic Version Of Vytorin (Ezetimibe/Simvastatin Tablets) 4/27/2017 6:35:25 AM
IMPAX Labs (IPXL) To Report First Quarter 2017 Results On May 10, 2017 4/6/2017 12:45:24 PM
IMPAX Labs (IPXL) Announces Favorable Ruling Regarding Patent Validity For Zomig (Zolmitriptan) Nasal Spray 3/31/2017 8:23:58 AM
IMPAX Labs (IPXL) Names Paul M. Bisaro President and CEO 3/27/2017 8:21:11 AM